STERIS plc (NYSE:STE) Receives $275.20 Average Price Target from Analysts

STERIS plc (NYSE:STE) has been assigned an average rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $275.20.

Several research analysts have commented on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th.

STERIS Stock Up 1.1%

Shares of STERIS stock opened at $220.24 on Thursday. STERIS has a 12-month low of $204.90 and a 12-month high of $269.44. The firm has a market capitalization of $21.60 billion, a PE ratio of 30.72 and a beta of 1.05. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average is $246.98 and its 200-day moving average is $249.58.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.STERIS’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the business posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities analysts anticipate that STERIS will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.1%. The ex-dividend date was Tuesday, February 17th. STERIS’s payout ratio is presently 35.15%.

Insider Transactions at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.07% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of STE. Steigerwald Gordon & Koch Inc. purchased a new position in STERIS during the 3rd quarter valued at about $25,000. Board of the Pension Protection Fund acquired a new position in shares of STERIS in the 4th quarter valued at about $25,000. Harbor Investment Advisory LLC lifted its position in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 60 shares in the last quarter. Activest Wealth Management boosted its holdings in shares of STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new stake in shares of STERIS during the fourth quarter worth approximately $28,000. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.